Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI broadly unchanged from a year ago

Accumulated OCI stood at $6K at the end of Q1 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6K+0.0% QoQ
Last fiscal yearDec 2025
$6K-0.0% YoY
Year agoMar 2025
$6K+0.0% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year-0.0%——
3-year CAGR+0.0%——
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
6K USD
Year-over-year change
-0.0%
4-year CAGR
+0.0%

Accumulated OCI vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's Mar 2026 Accumulated OCI of $6K is the highest of the 10 companies compared; the peer median is -$460K.
  • Its year-over-year change of +0.0% is the 2nd highest of 8, against a peer median of -209.5%.
  • Accumulated OCI amounts to 0.0% of total assets for AKBA, versus a peer median of 0.1%.
AKBA Competitors Peer median
Accumulated OCI for AKBA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AKBAAkebia Therapeutics, Inc.Mar 2026$6K +0.0%+0.0%0.0%
PRTAProthena Corporation plcMar 2026$0 ——0.0%
RIGLRigel Pharmaceuticals, Inc.Mar 2026-$128K -6300.0%—0.0%
CMPXCompass Therapeutics, Inc.Mar 2026-$159K -183.7%—0.1%
FDMT4D Molecular Therapeutics, Inc.Mar 2026-$180K -154.2%—0.0%
OLMAOlema Pharmaceuticals, Inc.Mar 2026-$460K -209.5%—0.1%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026-$1.13M +10.2%—0.4%
ZVRAZevra Therapeutics, Inc.Mar 2026-$1.8M -2091.5%—0.6%
GOSSGossamer Bio, Inc.Mar 2026-$4.02M -388.3%—3.1%
KALVKalVista Pharmaceuticals, Inc.Dec 2025-$7.13M ——2.1%
Peer median (excluding AKBA) -$460K-209.5%—0.1%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents149.8M90.47M42.93M51.87M184.84M
Short-term Investments00000
Net Receivables51.58M40.28M39.29M34.37M47.03M
Inventory36.63M21.57M15.69M16.24M15.61M
Other Current Assets032.86M20.24M7.32M(62.64M)
Total Current Assets271.15M185.18M118.15M113.83M184.84M
Property, Plant & Equipment (Net)40.61M34.37M16.05M10.42M0
Goodwill59.04M59.04M59.04M59.04M59.04M
Intangible Assets108.13M72.08M36.04M00
Long-term Investments00000
Tax Assets00000
Other Non-current Assets50.42M5.37M12.42M37.38M132.68M
Total Non-current Assets258.2M170.87M123.55M106.84M191.72M
Total Assets529.35M356.05M241.7M220.67M376.57M
Account Payables33.59M18.02M14.64M15.18M21.19M
Short-term Debt97.54M32M19.55M4.31M40.08M
Tax Payables00000
Deferred Revenue20.91M3.74M000
Other Current Liabilities31.18M52.53M18.26M22.75M101.67M
Total Current Liabilities261.05M129.54M99.87M80.91M162.94M
Long-term Debt53.08M34.08M71.2M175.47M176.21M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)21.47M43.3M43.3M00
Other Non-current Liabilities86.03M114.95M48.98M9.93M4.8M
Total Non-current Liabilities194.29M221.29M172.42M188.94M181.02M
Total Liabilities455.34M350.82M272.29M269.86M343.96M
Common Stock1K2K2K2K2K
Retained Earnings(1.46B)(1.56B)(1.61B)(1.68B)(1.68B)
Accumulated OCI6K6K6K6K6K
Other Stockholders Equity000(0)0
Minority Interest00000
Total Equity74.01M5.23M(30.58M)(49.19M)32.61M
Total Debt189.13M99.78M104.18M188.73M216.3M
Net Debt39.33M9.32M61.26M136.86M31.45M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.